Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2001

View Archived Issues

Delta Pharmaceuticals reports name change

Pharmacological profile of Ono-6818, an orally active HNE inhibitor, discussed at ATS meeting

Tripep provides update on lead drug candidate GPG

Viozan produces rapid and sustained activation of D2 receptors and beta2-adrenoceptors

Prostanoid receptor agonist protects against warm ischemia-reperfusion injury in rat kidneys

Company Profile: Apovia

Bimosiamose blocks kidney allograft rejection and is synergistic with other agents

Sepracor seeks FDA approval to evaluate new anxiolytic in humans

Ergo Science looking to sell or license Ergoset property rights

Posttranscriptional TNF inhibitor advances towards clinical trials for IBD

Femara approved in Canada as first-line treatment for advanced breast cancer

ID Biomedical begins clinical evaluation of intranasal influenza vaccine

Curcumin may have additional potential in acute pancreatitis

Hybridon completes sale of remaining shares in MethylGene

Development and commercialization rights to ISIS-113715 licensed by Merck

Dual antiinflammatory and antiproliferative effects reported for sPLA2 inhibitor

Dynavax initiates two new phase II/III trials for ragweed allergy treatment

Company Profile: EluSys Therapeutics

First patent for oral gene delivery owned by Genteric

Atherosclerosis inhibited by anti-MCP-1 gene therapy

Peptides based on Mcep sequence and use in tuberculosis vaccines

Ergoline derivatives synthesized at Novartis useful in depression, anxiety, etc.

Orally active, nontoxic antimicrobial agents in the Aventis pipeline

Merck describes new integrin receptor antagonists and therapeutic use thereof

Kissei researchers identify potential new treatments for diabetes and related disorders

Erythromycin derivatives with potent activity against staphylococci and streptococci

New serotonergic agents from BASF covered by U.S. patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...